To investigate the mechanism of antianginal action of the calcium channel blocker nisoldipine and to determine the reproducibility of the clinical and hemodynamic events induced by supine leg exercise, 30 patients with stable effort angina pectoris were studied. They were divided into two groups; one group of 19 patients received a single 10-mg dose of nisoldipine orally, and the other group of 11 patients received a single dose of placebo orally. Chest pain was induced in all of 30 patients during the control exercise test. After nisoldipine administration, chest pain was not induced in 13 of 19 patients and was of lessened severity in five patients with the same work load as those performing control exercise. ST segment at peak exercise showed less severe depression after nisoldipine. Systemic vascular resistance was reduced by 38% (p<0.001) at rest and 22% (p <0.001) at peak exercise, and coronary vascular resistance was reduced by 31% (p<0.01) at rest and 18% (p <0.01) at peak exercise. Pulmonary artery wedge pressure fell from 6±1 to 3±1 mm Hg (p<0.001) at rest and from 28±3 to 11+2 mm Hg (p<0.001) at peak exercise. Coronary sinus flow at rest and myocardial oxygen uptake both at rest and during exercise was not modified by nisoldipine. However, coronary sinus flow at peak exercise increased significantly from 219±24 to 249±31 ml/min (p<0.01) after nisoldipine, and myocardial oxygen uptake was not significantly changed despite decreased coronary vascular resistance. The clinical and hemodynamic events induced by the exercise during invasive studies (except pulmonary artery wedge pressure at rest) were reproducible after placebo administration. Our data demonstrate that increased coronary blood flow could be the major mechanism of the antianginal action of nisoldipine in supine leg exercise-induced angina. (Circulation 1990;81:1887-1898 
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Nisoldipine is a calcium channel blocker of the dihydropyridine class, similar in chemical structure to nifedipine,910 and exhibits greater smooth muscle selectivity than the parent compound, resulting in more potency as a vasodilator with fewer myocardial depressant effects. 10 Oral administration of nisoldipine has been shown to have antianginal effects in recent clinical trials.1"12 However, it is still unclear (sec)  1  55  M  75  0  0  None  83  Normal  600  2  45  M  0  100  90  Fair  75  Anterior hypokinesia  540  3  66  M  95  0  0  None  74  Normal  615  4  71  M  75  50  99  Good  79  Normal  540  5  60  F  99  50  0  Fair  80   Anterior hypokinesia   255  6  38  M  95  99  100  Fair  62   Anterior hypokinesia   270  7  55  M  0  100  0  Good  74  Normal  405  8 The main purposes of the present study was to evaluate the effect of nisoldipine on systemic and coronary hemodynamics in dynamic exercise-induced angina pectoris and to elucidate its antianginal mechanisms in patients with stable effort angina pectoris subjected to supine leg exercise before and after oral administration of a single dose of 10 mg nisoldipine. The study was also designed to determine whether the clinical and hemodynamic events induced by supine leg exercise during invasive studies are reproducible after placebo administration in patients with stable effort angina pectoris.
Methods

Patients
The study group consisted of 30 patients (29 men and one woman) with stable effort angina pectoris (age, 38-71 years; mean age, 54 years). They were admitted to the Nagoya University Hospital for investigation of suspected coronary artery disease. They were randomly (in a nonblinded manner) divided into two groups -one group of 19 patients who received a single 10 mg dose of nisoldipine orally (Table 1) , and another group of 11 patients who received a single dose of identical placebo orally ( Table 2 ). The groups were unequal in size because of the inability to obtain satisfactory coronary sinus blood flow measurements in some patients. Each patient had previous positive exercise tests with chest pain and significant ischemic ST-segment depression on angina-limited supine multistage bicycle ergometer exercise tests on at least 2 different days before the definitive study. These tests were done to familiarize patients with supine leg exercise and to avoid poor reproducibility of the exercise test results. This study was approved by an appropriate institutional review committee, and each patient gave informed consent.
Hemodynamic Studies
A triple-lumen thermistor Swan-Ganz catheter was positioned in the pulmonary artery percutaneously through the brachial vein to measure cardiac output and pulmonary artery wedge pressure. Thermodilution technique was used to determine cardiac output. The thermodilution curve, recorded with the thermodilution cardiac output computer (model Ri-5DCP, General Scanning Inc., Los Angeles, California), was checked for consistency before the results were accepted as reflecting cardiac output. Irregular (not smooth and not characterized by a rapid peak) curves, especially during exercise, were excluded from the study. A double-thermistor catheter (model Pulmonary artery wedge pressure, arterial pressure, cardiac output, and coronary sinus flow were measured at rest and every 3 minutes during exercise, at peak exercise, and 3 and 6 minutes after exercise. We could not obtain a measurement of coronary sinus flow in four patients either at rest or during exercise in the nisoldipine group.
Blood Sampling
Samples of blood for oxygen saturation were simultaneously obtained in the brachial artery, the pulmonary artery, and the coronary sinus at rest, at peak exercise, and 6 minutes after exercise in 11 of 19 patients in the nisoldipine group. Blood oxygen saturation was determined with a hemoximeter (model ABL3, Radiometer, Copenhagen, Denmark). Some parts of the sample were packed in dry ice for later determination of norepinephrine levels by a modification of a method described by de Champlain et al. 18 Samples of blood for nisoldipine plasma levels were obtained at 0.5, 1, 1.5, 2, 3, and 5 hours after nisoldipine administration. The total plasma concentration of nisoldipine and its active metabolites (as nisoldipine equivalent) were measured by radioreceptor assay. 19 
Angiographic Assessment of Coronary Stenosis
Selective coronary arteriography and left ventriculography were performed in all patients studied using the Sones technique in the same day after the nisoldipine or the placebo study. Left 
Statistics
Hemodynamic variables at rest and at peak exercise were compared between the control period and the nisoldipine period or the placebo period, respectively, using a paired t test. Pulmonary artery wedge pressure, systemic vascular resistance, coronary sinus flow, and coronary vascular resistance measured during the exercise test in the control period were compared with those in the nisoldipine period using a paired t test; a p value of less than 0.05 was considered statistically significant. Linear regression analysis was made using myocardial oxygen uptake during the exercise test before nisoldipine as an independent variable and after nisoldipine as a dependent one. The symptom-limited bicycle ergometer exercise duration of the subjects in nisoldipine group of 19 patients ranged from 220 to 660 seconds (mean, 440±34 seconds) ( Table 1) . Chest pain was induced in all 19 patients studied during the control exercise test, but after nisoldipine administration, chest pain was not induced in 13 patients. In five patients, it was of lessened severity, and only one patient (8) showed the same severity of chest pain before and after nisoldipine administration.
Comparative analysis of exercise-induced ischemic ST-segment depression before and after nisoldipine administration was possible in all of 19 patients ( Figure 1 ). Exercise-induced ST-segment depression was lessened in severity in all 19 patients after nisoldipine administration. Mean ST-segment depression was 0.18±0.03 mV in the control period and was significantly reduced to 0.10±0.02 mV after nisoldipine administration (p <0.001).
Effects of Placebo on Exercise-Induced Chest Pain and Ischemic ST-Segment Depression
The symptom-limited bicycle ergometer exercise duration of the placebo group of 11 patients ranged from 240 to 620 seconds (mean, 418+35 seconds) Table 2 ). Chest pain was induced in all of 11 patients during the control exercise test and in 10 patients after placebo administration chest pain. In only one patient was pain of lessened severity. Comparative analysis of exercise-induced ischemic ST-segment depression before and after placebo administration was possible in all 11 patients. Exercise-induced STsegment depression was 0.17±0.02 mV in the control period and 0.16+0.03 mV in the placebo period; these changes were not significant. 
Effects of Nisoldipine on Systemic and Cardiac Hemodynamics
Heart rate increased from 64±2 to 79+3 beats/min (p<0.001) at rest and from 118±4 to 128±5 beats/min (p<0.001) at peak exercise, whereas systolic arterial pressure decreased from 159±6 to 130±4 mm Hg (p<0.001) at rest and from 196±8 to 174±5 mm Hg (p<0.001) at peak exercise. As a result, rate-pressure product during exercise testing was not significantly modified by nisoldipine administration. Cardiac index increased from 2. at peak exercise after nisoldipine administration. In the control exercise test, a marked elevation of pulmonary artery wedge pressure with an increase in work load was observed, whereas after nisoldipine administration the pressure decreased significantly throughout the exercise test (Figure 2 ). Pulmonary artery wedge pressure fell from 6 + 1 to 3 + 1 mm Hg (p<0.001) at rest and from 28+3 to 11+2 mmHg (p<O.001) at peak exercise after nisoldipine administration. Systemic vascular resistance decreased significantly throughout the exercise test after nisoldipine administration ( Figure 3 ).
Effects of Nisoldipine on Coronary Hemodynamics
Comparative analysis of coronary blood flow was permitted in 15 of 19 patients studied during bicycle ergometer exercise testings (Tables 4 and 5 ). In the control study, exercise induced an increase in coronary sinus flow and a decrease in coronary vascular resistance. After administration of nisoldipine, coronary sinus flow significantly increased from 219 to 249 ml/min (p<0.01) at peak exercise (Figure 4 ). Coronary vascular resistance decreased from 1.30+±0.10 to 0.90+±0.09 mm Hg/ml/min (p<0.01) at rest and from 0.71+0.08 to 0.58±0.07 mm Hg/ml/min (p<0.01) at peak exercise after nisoldipine administration (Figure 5) . Arteriocoronary sinus oxygen difference showed no significant difference at rest or at peak exercise. Myocardial oxygen uptake showed no significant difference throughout the exercise test after nisoldipine administration ( Figure 6 ). Effects of Placebo on Systemic, Cardiac, and Coronary Hemodynamics Systemic, cardiac, and coronary hemodynamic measurements including heart rate, rate-pressure product, cardiac index, and coronary sinus flow showed no significant changes at rest and at peak exercise after placebo administration ( Arterial Cathecholamine Levels Arterial norepinephrine levels tended to increase at rest and at peak exercise in nisoldipine period (Table 3 ). However, this increase was not significant.
Plasma Concentration of Nisoldipine
The total plasma concentration-time data of nisoldipine and its active metabolites after a single oral dose of 10 mg were fit to a one-compartment model for seven patients. Nisoldipine was rapidly absorbed with Tma, ( 24 hours after nisoldipine administration. Crean et a120 also reported that treadmill exercise duration increased significantly after 5-and 20-mg nisoldipine administration. Accordingly, the 10-mg oral dose of nisoldipine used in the present study seems to be appropriate for a single-dose study.
Systemic Hemodynamic Effects of Nisoldipine
Major changes in the systemic hemodynamic response after a single oral dose of nisoldipine myocardial oxygen uptake,32 was not modified at all by nisoldipine administration. An increase in heart rate would be caused by a reflex sympathetic stimulating action originating from marked dilation of systemic vascular vessels as in the case of other calcium channel blockers based on dihydropyridine derivatives.33
Arterial norepinephrine levels in the present study tended to increase at rest and at peak exercise after nisoldipine administration; this is considered to be a result of a reflex increase in sympathetic activity.33 The precise mechanism, however, remains unclear. Increased sympathetic activity may produce an oxygen-wasting effect by increasing inotropic state.
Coronary Hemodynamic Effects of Nisoldipine
Myocardial oxygen uptake during supine leg exercise testings was not significantly modified by nisoldipine administration. Coronary vascular resistance was markedly reduced after nisoldipine administration, which did not result in an increased coronary sinus flow at rest because of nisoldipine-induced hypotension and the associated decrease in coronary perfusion pressure. However, coronary sinus flow at peak exercise showed a significant increase after nisoldipine administration. This increase in coronary blood flow may play an important role in the mechanism of antianginal action of nisoldipine. Tumas et a134 have reported no effects of nisoldipine on myocardial blood flow. There are several reports in which nisoldipine increased coronary blood flow despite a decrease in systemic blood pressure at rest. 35, 36 There are very few reports, however, about the effects of nisoldipine on coronary blood flow during dynamic exercise in patients with effort angina pectoris.
Previous investigators have suggested that exercise may induce positional catheter changes, thereby increasing variability among repeated thermodilution measurements of coronary sinus flow.3738 However, Magorien et a139 found a highly significant correlation between the measurement obtained during exercise.
In the present study, we displayed the thermodilution curves on a multichannel recorder. Irregular curves were discarded to keep reliability of the data and to avoid contamination by right atrial blood.
Antianginal Mechanism of Nisoldipine
The mechanisms of antianginal action of calcium channel blockers have been considered to involve a decrease in myocardial oxygen uptake, an increase in coronary blood flow, improvement in the distribution of coronary blood flow, an increase in collateral blood flow, and protective action on the myocardium.
In the present study, nisoldipine administration induced no evident changes in myocardial oxygen uptake. Rate-pressure product also showed no significant changes after nisoldipine administration. As the result, a reduction in myocardial oxygen uptake could not be a major factor of the antianginal action of nisoldipine. Coronary blood flow is one of the principal factors regulating myocardial oxygen supply. Because approximately 85% of coronary sinus blood flow arises from the left ventricle, measurements of coronary sinus flow reflect left ventricular coronary blood flow. The present study suggests that the mechanism of protection by nisoldipine is mainly the result of an increase in coronary blood flow.
The calcium channel blockers nifedipine and diltiazem have been found to inhibit ischemia-induced vasodilation of the resistance vessels after the acute dilation has resolved.4041 In the presence of a proximal coronary stenosis, ischemic vasodilation of the coronary resistance vessels causes a decrease in perfusion pressure distal to the stenosis and loss of the ability for local autoregulation. These effects may result in redistribution of coronary blood flow away from the subendocardium.42A3 Nifedipine has been found to attenuate this redistribution of coronary blood flow and to increase subendocardial flow,41 possibly by blunting the intense vasodilator response to ischemia.44 Heusch et a145 have demonstrated the presence of significant coronary vasodilator reserve during exercise-induced myocardial ischemia in conscious dogs and that nifedipine can recruit this reserve and induce an improvement of ischemic regional myocardial blood flow and function without major effects on systemic hemodynamics. One of the possible antianginal mechanisms of nisoldipine would be an improvement in the distribution of coronary blood flow to the subendocardium. The improved myocardial relaxation and diastolic compliance produced by nisoldipine like nifedipine46 could have been a possible contributing factor to the increase in myocardial blood flow by increasing the perfusion pressure gradient to the subendocardium. 47 Waltier et a148 have reported that nisoldipine increase coronary collateral blood flow to the ischemic zone with equal distribution to the subendocardium and epicardium in dogs with acutely occluded left anterior descending arteries. In the present study, seven of 19 patients did not show collateral filling, whereas their exercise-induced ischemic STsegment depression improved and their exerciseinduced chest pain was not induced or was of lessened severity after nisoldipine administration. These results may suggest that an increase in collateral blood flow could not be a principal mechanism of antianginal action of nisoldipine in humans.
In addition to modulating coronary blood flow, nisoldipine could be involved in a variety of calciumdependent processes to protect myocardium from ischemia including reduction of nucleotide breakdown,49 stabilization of membrane permeability,50 protection of the integrity of sarcolemmal membranes,51 and inhibition of leukotriene actions.52
Any combination of these or other factors may play an important role in the mechanism of protection by nisoldipine from acute myocardial ischemia, but we could not distinguish among any of these mechanisms in the present study.
Reproducibility of Exercise Test Results
When the symptom-limited bicycle ergometer exercise test was performed in patients with stable effort angina pectoris, the exercise time, heart rate, and left ventricular end-diastolic pressure for evaluation of left ventricular function have been generally said to be reproducible.53,54 In the present study, the clinical and hemodynamic events induced by supine leg exercise during invasive studies were reproducible after placebo administration in patients with stable effort angina pectoris. Excellent reproducibility was demonstrated in heart rate, rate-pressure product, and cardiac output as well as coronary sinus flow and coronary vascular resistance both at rest and at peak exercise. Only pulmonary artery wedge pressure at rest dropped significantly, compared with control study, after placebo administration. However, this pressure at peak exercise was not affected at all by placebo administration. Accordingly, the hemodynamic effects of nisoldipine, except pulmonary artery wedge pressure at rest, observed in this study should be reliable.
Pharmacokinetics of Nisoldipine
In the present study the total plasma concentration of nisoldipine and its active metabolites reached a peak 1.6 hours after administration, and the elimination half-life was 1.3 hours. The bicycle ergometer exercise test was performed 1.5 hours after nisoldipine administration, and it should be possible to obtain sufficient effects of nisoldipine at this time. Despite this short half-life the pharmacodynamic effect of nisoldipine was shown to persist for a much longer period.12,21 This discrepancy may be due to tissue binding or to formation of an active metabolite. Recently it has been elucidated that nisoldipine has three active metabolites and exhibits dose-proportional pharmacokinetics at oral dose from 2.5 to 20 mg.54
Limitation of Study
Dynamic exercise tests with invasive hemodynamic studies may be the most important practical test to elucidate the mechanism of antianginal drugs in patients with effort angina pectoris. However, this invasive study may have some limitations. In this study nisoldipine or placebo was always given after the control exercise. A possible order effect of this study design cannot be denied. However, as nisoldipine has a long pharmacodynamic effect, it was not possible to reverse the order of exercise tests with invasive hemodynamic monitoring. For the same reason, this was a study of only a single dose of nisoldipine since repeated invasive studies could not be justified. An 
